Dr Reddy's Laboratories launches cholesterol lowering drug in US

The drug is the generic version of MSD International's Vytorin (ezetimibe & simvastatin) tablet

Dr Reddy's completes acquisition of product portfolio from Teva
BS B2B Bureau Hyderabad
Last Updated : May 02 2017 | 1:29 PM IST
Dr Reddy’s Laboratories Ltd has launched cholesterol lowering drug - ezetimibe and simvastatin tablet in strengthens of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg - in the US. The drug is the generic version of MSD International GmbH’s Vytorin tablet. Dr Reddy’s is among the first companies to launch the generic product in the US market.

The Vytorin brand had US sales of approximately $ 678 million MAT for the most recent twelve months ended in February 2017 according to IMS Health. Vytorin reduces the levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in blood, while increasing levels of good cholesterol (high-density lipoprotein, or HDL).

Dr Reddy’s ezetimibe and simvastatin tablets will be available in bottle count sizes of 30, 90 and 1000.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story